What is cagrilintide and how does it differ from semaglutide Cagrilintide: Long-acting amylin analog What cagrilintide is: Synthetic analog of amylin (human hormone) Long-acting formulation (weekly dosing) Developed by Novo Nordisk Currently in Phase 3 clinical trials Not yet FDA approved (as of 2024) Paired with semaglutide as "CagriSema" How amylin works naturally: Co-secreted with insulin from pancreatic beta cells Released after meals Slows gastric emptying (food stays in stomach longer) Reduces glucagon secretion Signals satiety to brain Regulates postprandial glucose Cagrilintide's mechanisms: Mimics natural amylin but lasts much longer Dramatically slows gastric emptying Increases satiety and fullness Reduces food intake Lowers postprandial glucose Works on amylin receptors (different from GLP-1) Primary benefits: Powerful appetite suppression Extended feeling of fullness Reduced meal frequency Lower caloric intake Glucose regulation Complements GLP-1 action Learn about peptides , how peptides work , and what are peptides used for in our foundational guides
Youre probably familiar with the many benefits of vitamin C for skin, bones, and your immune system
Resets the ubiquitin-proteasome system to clear damaged proteins
The published research on oral B12 bioavailability consistently shows around 1% absorption meaning of a 1000mcg oral dose, only about 10mcg actually reaches your cells
notably, glucose was maintained in the normal range [100]
Contrary to alternative method based on a competitive hypothesis, GSVA is based on self-contained null hypothesis which analyzes each gene set in isolation, assessing differential expression of the gene set without comparing to a background [62, 63]
